AU1451900A - Use of optically pure (r)-tofisopam for treating and preventing anxiety disorders and composition thereof - Google Patents

Use of optically pure (r)-tofisopam for treating and preventing anxiety disorders and composition thereof Download PDF

Info

Publication number
AU1451900A
AU1451900A AU14519/00A AU1451900A AU1451900A AU 1451900 A AU1451900 A AU 1451900A AU 14519/00 A AU14519/00 A AU 14519/00A AU 1451900 A AU1451900 A AU 1451900A AU 1451900 A AU1451900 A AU 1451900A
Authority
AU
Australia
Prior art keywords
anxiety
tofisopam
disorder
anxiety disorder
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU14519/00A
Other languages
English (en)
Inventor
Donald F. Klein
Donald W Landry
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vela Pharmaceuticals Inc
Original Assignee
Janus Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janus Pharmaceuticals Inc filed Critical Janus Pharmaceuticals Inc
Publication of AU1451900A publication Critical patent/AU1451900A/en
Priority to AU2005201012A priority Critical patent/AU2005201012A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrane Compounds (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
AU14519/00A 1998-10-27 1999-10-27 Use of optically pure (r)-tofisopam for treating and preventing anxiety disorders and composition thereof Abandoned AU1451900A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2005201012A AU2005201012A1 (en) 1998-10-27 2005-03-07 Use of Optically Pure (R)-Tofisopam for Treating and Preventing Anxiety Disorders and Composition Thereof

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10580398P 1998-10-27 1998-10-27
US60105803 1998-10-27
PCT/US1999/025040 WO2000024400A1 (en) 1998-10-27 1999-10-27 Use of optically pure (r)-tofisopam for treating and preventing anxiety disorders and composition thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2005201012A Division AU2005201012A1 (en) 1998-10-27 2005-03-07 Use of Optically Pure (R)-Tofisopam for Treating and Preventing Anxiety Disorders and Composition Thereof

Publications (1)

Publication Number Publication Date
AU1451900A true AU1451900A (en) 2000-05-15

Family

ID=22307874

Family Applications (1)

Application Number Title Priority Date Filing Date
AU14519/00A Abandoned AU1451900A (en) 1998-10-27 1999-10-27 Use of optically pure (r)-tofisopam for treating and preventing anxiety disorders and composition thereof

Country Status (16)

Country Link
EP (1) EP1124556B1 (OSRAM)
JP (2) JP2003522112A (OSRAM)
AT (1) ATE269705T1 (OSRAM)
AU (1) AU1451900A (OSRAM)
BR (1) BR9914899A (OSRAM)
CA (1) CA2348281A1 (OSRAM)
DE (1) DE69918322T2 (OSRAM)
DK (1) DK1124556T3 (OSRAM)
ES (1) ES2224751T3 (OSRAM)
GB (1) GB2367748A (OSRAM)
HK (2) HK1046500A1 (OSRAM)
IL (2) IL142803A0 (OSRAM)
NZ (1) NZ511744A (OSRAM)
PT (1) PT1124556E (OSRAM)
WO (1) WO2000024400A1 (OSRAM)
ZA (1) ZA200103376B (OSRAM)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6649607B2 (en) * 2001-05-18 2003-11-18 Vela Pharmaceuticals, Inc. Compositions and methods for treating or preventing convulsions or seizures
CN1662231A (zh) * 2002-04-24 2005-08-31 柏树生物科学公司 包括应激相关障碍在内的功能性躯体障碍的预防与治疗
US6638928B1 (en) * 2002-12-03 2003-10-28 Vela Pharmaceuticals, Inc. Treatment of irritable bowel syndrome and nonulcer dyspepsia with substituted 2,3-benzodiazepines
US20040152695A1 (en) * 2002-12-03 2004-08-05 Vela Pharmaceuticals, Inc. Pharmaceutical composition of 1-(3-hydroxy-4-methoxyphenyl)-4-methyl-5-ethyl-7,8-dimethoxy-5H-2,3-benzodiazepine and uses thereof
JP2006510634A (ja) 2002-12-03 2006-03-30 ヴェラ ファーマスーティカルズ インコーポレイテッド １−（３，４−ジメトキシフェニル）−４−メチル−５−エチル−７−メトキシ−８−ヒドロキシ−５ｈ−２，３−ベンゾジアゼピンの製薬組成物及びその用途
US6864251B2 (en) * 2002-12-03 2005-03-08 Vela Pharmaceuticals, Inc. Treatment of LTB4-mediated inflammatory disorders with optically-pure (R)-2,3-benzodiazepines
US7022700B2 (en) 2002-12-03 2006-04-04 Vela Pharmaceuticals, Inc. Method of increasing neutrophil production using optically-pure (R)-2,3-benzodiazepines
CA2525273C (en) * 2003-05-16 2012-04-17 Vela Pharmaceuticals, Inc. Treatment of gastrointestinal dysfunction and related stress with an enantiomerically-pure (r) 2,3-benzodiazepine
JP2007513171A (ja) * 2003-12-03 2007-05-24 ヴェラ ファーマスーティカルズ インコーポレイテッド ２，３−ベンゾジアゼピン低投与量による上皮の炎症性疾患の治療
FR2870539B1 (fr) * 2004-05-19 2006-08-04 Greenpharma Sa Sa Nouvelles methodes et medicaments
US7541355B2 (en) 2005-05-23 2009-06-02 Vela Acquisition Corporation Conversion process for 2,3-benzodiazepine enantiomers
CN102836162A (zh) * 2012-04-10 2012-12-26 珠海亿邦制药股份有限公司 一种以托非索泮为活性成分的口服固体制剂及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK118660B (da) * 1966-12-09 1970-09-21 Egyt Gyogyszervegyeszeti Gyar Analogifremgangsmåde til fremstilling af 1-(3',4'-dimethoxyphenyl)-3-methyl-4-ethyl-6,7-dimethoxy-isoquinolin-N-imid.
ZA712798B (en) * 1970-11-06 1972-02-23 Egyt Gyogyszervegyeszeti Gyar New,pharmaceutically active 2,3-diazabicyclo(5.4.0)undecapentaene derivative and process for preparing same
HU178516B (en) * 1978-05-05 1982-05-28 Egyt Gyogyszervegyeszeti Gyar Process for producing enanthiomeres of 1-bracket-3,4-dimethoxy-phenyl-bracket closed-5-ethyl-7,8-dimethoxy-4-methyl-5h-2,3-benzodiazepine and pharmacologically acceptable soles of the /-/-enanthiomere
HU209530B (en) * 1988-08-31 1994-07-28 Magnezitipari Muevek Rt Process for manufacturing of cromit-like, fire resistant materials

Also Published As

Publication number Publication date
DE69918322D1 (de) 2004-07-29
GB0111739D0 (en) 2001-07-04
JP2007211028A (ja) 2007-08-23
GB2367748A (en) 2002-04-17
ATE269705T1 (de) 2004-07-15
ES2224751T3 (es) 2005-03-01
CA2348281A1 (en) 2000-05-04
HK1046500A1 (zh) 2003-01-17
GB2367748A8 (en) 2002-12-19
HK1040908A1 (en) 2002-06-28
DK1124556T3 (da) 2004-10-11
EP1124556A1 (en) 2001-08-22
BR9914899A (pt) 2001-07-17
NZ511744A (en) 2004-04-30
IL142803A (en) 2006-10-05
IL142803A0 (en) 2002-03-10
WO2000024400A1 (en) 2000-05-04
ZA200103376B (en) 2003-09-09
EP1124556B1 (en) 2004-06-23
PT1124556E (pt) 2004-10-29
HK1040908B (en) 2005-04-22
JP2003522112A (ja) 2003-07-22
DE69918322T2 (de) 2005-09-15

Similar Documents

Publication Publication Date Title
US6080736A (en) Methods and compositions for treating and preventing anxiety and anxiety disorders using optically pure (R) tofisopam
JP2007211028A (ja) 不安障害の処置および予防への光学的に純粋な（ｒ）−トフィソパムの使用およびその組成物
Cohen et al. Evidence for the involvement of dopamine receptors in ethanol-induced hyperactivity in mice
KR20200021477A (ko) Nmdar 길항제-반응성 신경정신 질환을 위한 병용 요법
EP2185155A1 (en) Pharmaceutical compositions containing dopamine receptor ligands and methods of treatment using dopamine recptor ligands
US8735389B2 (en) Treating psychological conditions using muscarinic receptor M1 antagonists
WO2008070000A2 (en) Treatment of anxiety with eszopiclone
Ciraulo et al. Sedative hypnotics
Pinder Designing a new generation of antidepressant drugs
JP2003522112A5 (OSRAM)
AU2005201012A1 (en) Use of Optically Pure (R)-Tofisopam for Treating and Preventing Anxiety Disorders and Composition Thereof
Fasipe Moving from the old monoaminergic theory toward the emerging hypothesis in the rational design of rapid-onset novel antidepressants
OWEN et al. Molindone hydrochloride: a review of laboratory and clinical findings
KR102609676B1 (ko) Nmda 길항제 및 d2/5ht2a 또는 선택적 5ht2a 길항제를 이용한 우울증의 치료
Fasipe et al. Announcing the first novel class of rapid-onset antidepressants in clinical practice
MXPA01004109A (en) Use of optically pure (r)-tofisopam for treating and preventing anxiety disorders and composition thereof
CN101472571A (zh) 使用毒蕈碱型受体m1拮抗剂治疗心理学病况
Preskorn et al. Other antidepressants
Joo The role of the AMPA receptor GluR2 subunit in anesthetic neurodepression and excitotoxic cell death